- Mindray Bio-Medical’s net income for the first half of 2025 decreased by 33% year-over-year, amounting to 5.07 billion yuan.
- This net income result missed the estimated figure of 6.61 billion yuan.
- Revenue also saw a decline, dropping by 18% year-over-year to reach 16.74 billion yuan.
- Revenue fell short of the expected 19.37 billion yuan.
- Despite the decline in financial performance, the company maintains strong market confidence with 40 buy ratings and no hold or sell ratings.
- Comparisons are based on previously disclosed company data.
A look at Shenzhen Mindray Bio-Medical Electronics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shenzhen Mindray Bio-Medical Electronics, a company specializing in manufacturing and distributing medical equipment, shows a mixed outlook based on the Smartkarma Smart Scores. While the company excels in areas such as dividends, growth, resilience, and overall financial health, it falls short in terms of value and momentum. With high scores in dividends and resilience, investors can expect a steady income stream and a company that can weather market uncertainties well. However, the lower value and momentum scores indicate that the stock may not be undervalued and could potentially lack the strong upward price movement that some investors seek.
In summary, Shenzhen Mindray Bio-Medical Electronics is a company known for producing a wide range of medical equipment, including life information supporting, in vitro diagnostic, and medical imaging equipment, along with supporting reagents. Despite its strengths in dividends, growth, and resilience, investors may want to carefully consider its current valuation and momentum before making investment decisions in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
